NCT02392572 2026-03-12
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT02863991 2024-07-03
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Jazz Pharmaceuticals
Phase 1/2 Terminated
NCT02420795 2022-04-04
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02038699 2021-04-30
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 1/2 Withdrawn